Aetna · Cftr Trikafta · US health-plan appeal rights

Cftr Trikafta denied for failing step therapy by Aetna?

Q: How long do I have to appeal a Aetna Cftr Trikafta denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Aetna typically requires

Aetna's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Aetna Clinical Policy Bulletin (Cystic Fibrosis Modulator Therapy)

The Aetna angle on Cftr Trikafta

## Why Aetna Applies Step Therapy to Trikafta

Step therapy (also called "fail-first") requires a patient to try one or more alternative drugs before the plan will authorize the requested medication. For Trikafta, step-therapy denials typically arise when Aetna's policy requires documentation that a prior-generation CFTR modulator was tried and failed, or when the patient's mutation profile is one for which an older modulator exists but may be less effective.

Step therapy for a genotype-specific disease like cystic fibrosis is frequently overturned because the clinical and genetic record can establish that the required "step" drug is not indicated for the patient's specific mutation, or that the treating clinician has a documented clinical reason to start with the superior agent.

## Your Federal Appeal Rights

Step-therapy exception request: Many states have enacted step-therapy exception laws requiring plans to waive the step when a prior-step drug is contraindicated, not indicated for the patient's diagnosis, or when the patient has already tried it. Federal plans must also grant exceptions in defined circumstances. File this request immediately.
Internal appeal: File within the deadline on the denial letter. Request Aetna's written step-therapy criteria for this drug class.
External review (ACA §2719 / ERISA §503): Available after the internal appeal. External reviewers assess whether the plan's step requirement is consistent with clinical evidence and professional guidelines. The window is approximately 4 months from the final denial.
Expedited track: Request if your health would be seriously jeopardized by a treatment delay.

## Documentation to Gather

1. Genetic mutation report: If the required step drug is not FDA-approved for your patient's mutation, the label is your primary evidence. Confirm which mutations each prior-step drug covers and which it does not. 2. Prior treatment history: If the patient previously tried the step drug—in any context, including as part of another plan or as a compassionate-use patient—document it with dates and clinical outcomes. 3. Prescriber step-exception letter: The letter should explain, specifically and clinically, why the required step drug is (a) not indicated for this patient's genotype, (b) was previously tried and failed, or (c) would cause clinically unacceptable risk given this patient's current status. Reference the applicable CF Foundation care guidelines. 4. State step-therapy exception law (if applicable): Research whether your state has enacted step-therapy protections. Many do, and citing the applicable state statute strengthens the exception request.

## Criteria-Mapping Structure

| Step-Therapy Exception Ground | Supporting Evidence | |---|---| | Required step drug not indicated for patient's genotype | FDA labels for both drugs + genetic report | | Patient previously tried required step drug | Medical records with dates + outcomes | | Clinical contraindication to step drug | Prescriber letter with clinical rationale | | State law exception applies | State statute citation + plan type confirmation |

The strongest step-therapy appeals are genetic: if the label for the required step drug simply does not cover the patient's mutation class, the step requirement has no clinical foundation and should not survive external review.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Aetna appeals

Other insurers on Cftr Trikafta

Other denial reasons for Aetna Cftr Trikafta

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.